Status:
RECRUITING
Respiratory Training in the Treatment of Transdiagnostic Pathological Anxiety
Lead Sponsor:
University of Texas at Austin
Collaborating Sponsors:
Freespira, Inc.
Conditions:
Anxiety Disorders
Trauma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Purpose of the Research: The primary aim of the proposed study is to conduct a randomized parallel-group 2-arm clinical trial investigating capnometry-guided respiratory intervention (CGRI) for pathol...
Detailed Description
Low end-tidal CO2 (ETCO2), which is an accompanying feature of hyperventilation, has been associated with a variety of anxiety disorders, including panic disorder and social phobia. More recently, res...
Eligibility Criteria
Inclusion
- Clinically elevated anxiety as indicated by an eight or higher on the Overall Anxiety Severity and Impairment Scale (OASIS).
- Meets DSM-5 criteria for one or more of the following anxiety or trauma-related disorders as their "primary" mental disorder:
- Generalized Anxiety Disorder
- Panic Disorder
- Health Anxiety
- Agoraphobia
- Social Anxiety Disorder
- Posttraumatic Stress Disorder
- Acute Stress Disorder
- Adjustment Disorder with primary anxious mood
- Anxiety disorder not otherwise specified
- No current use of psychotropic medications or stable on current medications for at least 6 weeks
- Age 18+.
- Able to arrange transportation to our laboratory for study appointments.
- Fluent in English.
Exclusion
- No history of medical conditions that would contraindicate participation in fear-provocation or respiratory challenges, including:
- Cardiovascular or respiratory disorders
- High blood pressure
- Epilepsy
- Strokes
- Seizures
- History of fainting
- Pregnant or lactating
- Not currently receiving other psychological treatment for anxiety.
- No history of a suicide attempt within the past 6 months.
- No history of psychosis within the past 6 months.
- No history of moderate to severe alcohol or substance use disorder (with the exception of nicotine) within the past 3 months.
- Does not endorse COVID-19 symptoms during the screening phase.
Key Trial Info
Start Date :
August 22 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2027
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT05427708
Start Date
August 22 2022
End Date
May 1 2027
Last Update
August 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Texas at Austin
Austin, Texas, United States, 78712